Abstract:Introduction Previous studies have explored prediction value of serum metabolites in neoadjuvant chemoradiation therapy (NCRT) response for rectal cancer. To date, limited literature is available for serum metabolome changes dynamically through NCRT. Objectives This study aimed to explore temporal change pattern of serum metabolites during NCRT, and potential metabolic biomarkers to predict the pathological response to NCRT in locally advanced rectal cancer (LARC) patients. Methods Based on dynamic UHPLC-QTOF-MS untargeted metabolomics design, this study included 106 LARC patients treated with NCRT. Biological samples of the enrolled patients were collected in five consecutive time-points. Untargeted metabolomics was used to profile serum metabolic signatures from LARC patients. Then, we used fuzzy C-means clustering (FCM) to explore temporal change patterns in metabolites cluster and identify monotonously changing metabolites during NCRT. Repeated measure analysis of variance (RM-ANOVA) and multilevel partial least-squares discriminant analysis (ML-PLS-DA) were performed to select metabolic biomarkers. Finally, a panel of dynamic differential metabolites was used to build logistic regression prediction models. Results Metabolite profiles showed a clearly tendency of separation between different follow-up panels. We identified two clusters of 155 serum metabolites with monotonously changing patterns during NCRT (74 decreased metabolites and 81 increased metabolites). Using RM-ANOVA and ML-PLS-DA, 8 metabolites (L-Norleucine, Betaine, Hypoxanthine, Acetylcholine, 1-Hexadecanoyl-sn-glycero-3-phosphocholine, Glycerophosphocholine, Alpha-ketoisovaleric acid, N-Acetyl-L-alanine) were further identified as dynamic differential biomarkers for predicting NCRT sensitivity. The area under the ROC curve (AUC) of prediction model combined with the baseline measurement was 0.54 (95%CI = 0.43 ~ 0.65). By incorporating the variability indexes of 8 dynamic differential metabolites, the prediction model showed better discrimination performance than baseline measurement, with AUC = 0.67 (95%CI 0.57 ~ 0.77), 0.64 (0.53 ~ 0.75), 0.60 (0.50 ~ 0.71), and 0.56 (0.45 ~ 0.67) for the variability index of difference, linear slope, ratio, and standard deviation, respectively. Conclusion This study identified eight metabolites as dynamic differential biomarkers to discriminate NCRT-sensitive and resistant patients. The changes of metabolite level during NCRT show better performance in predicting NCRT sensitivity. These findings highlight the clinical significance of metabolites variabilities in metabolomics analysis.

Exploring Metabolomics Biomarkers for Evaluating the Effectiveness of Concurrent Radiochemotherapy for Cervical Cancers.

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Profiling Protein Markers Associated with the Sensitivity to Concurrent Chemoradiotherapy in Human Cervical Carcinoma.

Prognostic Biomarkers of Cervical Squamous Cell Carcinoma Identified Via Plasma Metabolomics.

A Metabolomics Approach for Predicting the Response to Neoadjuvant Chemotherapy in Cervical Cancer Patients

Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients

Analysis of Urinary Metabolites for Breast Cancer Patients Receiving Chemotherapy by Ce-Ms Coupled with On-Line Concentration

Plasma Metabolomics for the Assessment of the Progression of Non-Small Cell Lung Cancer

A Comprehensive Analysis Of Metabolomics And Transcriptomics In Cervical Cancer

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers*

Changes of Serum Metabolites Levels During Neoadjuvant Chemoradiation and Prediction of the Pathological Response in Locally Advanced Rectal Cancer

Predicting the Pathological Response to Neoadjuvant Chemoradiation Using Untargeted Metabolomics in Locally Advanced Rectal Cancer.

Alteration of Plasma Metabolites Associated with Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma Via Untargeted Metabolomics Approach

Plasma Metabolomic Analysis Of Human Hepatocellular Carcinoma: Diagnostic And Therapeutic Study

Diagnostic Potential of Ionomic Profile in the Plasma of Cervical Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

Data from Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Metabonomic Study of Lung Cancer and the Effects of Radiotherapy on Lung Cancer Patients: Analysis of Highly Polar Metabolites by Ultraperformance Hilic Coupled with Q-Tof Ms

Early Change In Metabolic Tumor Heterogeneity During Chemoradiotherapy And Its Prognostic Value For Patients With Locally Advanced Non-Small Cell Lung Cancer

Evaluating for correlations between metabolites in patients receiving immunotherapy for metastatic or recurrent NSCLC: an exploratory study based on two cohorts